BioGend Therapeutics (6733) reported revenue of NT$21.4 million for Oct 2026, +24.8% year on year and +0.0% from the previous month. Revenue for Jan–Oct 2026 was NT$196.1 million (+9.6% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 123 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$21.4 million | +24.8% | +0.0% |
| Sep 2026 | NT$21.4 million | +9.5% | +10.9% |
| Aug 2026 | NT$19.3 million | +9.3% | -2.2% |
| Jul 2026 | NT$19.7 million | -19.5% | -17.2% |
| Jun 2026 | NT$23.8 million | +63.6% | +48.7% |
| May 2026 | NT$16 million | -14.5% | -18.3% |
| Apr 2026 | NT$19.6 million | +0.9% | +18.0% |
| Mar 2026 | NT$16.6 million | +10.4% | +8.5% |
| Feb 2026 | NT$15.3 million | +1.4% | -33.5% |
| Jan 2026 | NT$23 million | +32.9% | -0.8% |
| Dec 2025 | NT$23.2 million | +15.5% | +15.2% |
| Nov 2025 | NT$20.1 million | +43.8% | +17.5% |
| Oct 2025 | NT$17.1 million | -0.8% | -12.3% |
| Sep 2025 | NT$19.5 million | +55.8% | +10.8% |
| Aug 2025 | NT$17.6 million | +9.7% | -28.0% |
| Jul 2025 | NT$24.5 million | +55.4% | +68.2% |
| Jun 2025 | NT$14.6 million | +59.7% | -22.3% |
| May 2025 | NT$18.7 million | +44.1% | -3.5% |
| Apr 2025 | NT$19.4 million | +28.1% | +29.1% |
| Mar 2025 | NT$15 million | -1.9% | -0.3% |
| Feb 2025 | NT$15.1 million | +79.6% | -12.9% |
| Jan 2025 | NT$17.3 million | +49.1% | -13.7% |
| Dec 2024 | NT$20.1 million | +82.5% | +43.4% |
| Nov 2024 | NT$14 million | +51.7% | -18.9% |
| Oct 2024 | NT$17.3 million | -3.5% | +37.8% |
Jan–Oct 2026 cumulative: NT$196.1 million (+9.6% YoY)
Other Biotech & Medical companies
Compare with peers: BioGend Therapeutics vs PEC / BioGend Therapeutics vs Lotus Pharm / BioGend Therapeutics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
係銷售醫療器材及抗生素之收入。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16